Robert R Raevis
Examiner (ID: 3738, Phone: (571)272-2204 , Office: P/2856 )
Most Active Art Unit | 2856 |
Art Unit(s) | 2607, 2212, 2605, 2855, 3621, 2502, 2856, 2861 |
Total Applications | 5754 |
Issued Applications | 4691 |
Pending Applications | 258 |
Abandoned Applications | 738 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16774207
[patent_doc_number] => 10985331
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-20
[patent_title] => Organic electroluminescent materials and devices
[patent_app_type] => utility
[patent_app_number] => 16/927297
[patent_app_country] => US
[patent_app_date] => 2020-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 9525
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 235
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16927297
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/927297 | Organic electroluminescent materials and devices | Jul 12, 2020 | Issued |
Array
(
[id] => 16770822
[patent_doc_number] => 10981910
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-20
[patent_title] => Biaryl kinase inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/913064
[patent_app_country] => US
[patent_app_date] => 2020-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 52511
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16913064
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/913064 | Biaryl kinase inhibitors | Jun 25, 2020 | Issued |
Array
(
[id] => 16649941
[patent_doc_number] => 10927103
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-02-23
[patent_title] => Organic electroluminescent compound and organic electroluminescent device comprising the same
[patent_app_type] => utility
[patent_app_number] => 16/897422
[patent_app_country] => US
[patent_app_date] => 2020-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7865
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 156
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16897422
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/897422 | Organic electroluminescent compound and organic electroluminescent device comprising the same | Jun 9, 2020 | Issued |
Array
(
[id] => 16800157
[patent_doc_number] => 10995078
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-05-04
[patent_title] => Compounds and compositions for inhibition of FASN
[patent_app_type] => utility
[patent_app_number] => 15/929751
[patent_app_country] => US
[patent_app_date] => 2020-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48370
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 2461
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15929751
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/929751 | Compounds and compositions for inhibition of FASN | May 19, 2020 | Issued |
Array
(
[id] => 16549717
[patent_doc_number] => 10882866
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-01-05
[patent_title] => Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/844473
[patent_app_country] => US
[patent_app_date] => 2020-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38421
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 488
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16844473
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/844473 | Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | Apr 8, 2020 | Issued |
Array
(
[id] => 16590512
[patent_doc_number] => 10899762
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-01-26
[patent_title] => Organic compounds
[patent_app_type] => utility
[patent_app_number] => 16/786240
[patent_app_country] => US
[patent_app_date] => 2020-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11976
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16786240
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/786240 | Organic compounds | Feb 9, 2020 | Issued |
Array
(
[id] => 16268771
[patent_doc_number] => 20200270258
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => NOVEL SELECTIVE PI3K DELTA INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/776327
[patent_app_country] => US
[patent_app_date] => 2020-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14054
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16776327
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/776327 | Selective PI3K delta inhibitors | Jan 28, 2020 | Issued |
Array
(
[id] => 15848103
[patent_doc_number] => 10639312
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2020-05-05
[patent_title] => Finished pharmaceutical dosage form of a methenamine salt such as methenamine mandelate
[patent_app_type] => utility
[patent_app_number] => 16/705414
[patent_app_country] => US
[patent_app_date] => 2019-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2817
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16705414
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/705414 | Finished pharmaceutical dosage form of a methenamine salt such as methenamine mandelate | Dec 5, 2019 | Issued |
Array
(
[id] => 15527079
[patent_doc_number] => 20200055845
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-20
[patent_title] => KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/661907
[patent_app_country] => US
[patent_app_date] => 2019-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 77164
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16661907
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/661907 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Oct 22, 2019 | Abandoned |
Array
(
[id] => 16649940
[patent_doc_number] => 10927102
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-02-23
[patent_title] => Crystalline forms of posaconazole intermediate and process for the preparation of amorphous posaconazole
[patent_app_type] => utility
[patent_app_number] => 16/655632
[patent_app_country] => US
[patent_app_date] => 2019-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 5074
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 118
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16655632
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/655632 | Crystalline forms of posaconazole intermediate and process for the preparation of amorphous posaconazole | Oct 16, 2019 | Issued |
Array
(
[id] => 16222695
[patent_doc_number] => 20200247811
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-06
[patent_title] => IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/593588
[patent_app_country] => US
[patent_app_date] => 2019-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10876
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16593588
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/593588 | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors | Oct 3, 2019 | Issued |
Array
(
[id] => 15768673
[patent_doc_number] => 20200115354
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-16
[patent_title] => THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/576569
[patent_app_country] => US
[patent_app_date] => 2019-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70857
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16576569
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/576569 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Sep 18, 2019 | Abandoned |
Array
(
[id] => 16369010
[patent_doc_number] => 10800750
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-13
[patent_title] => Compounds and compositions for inhibition of FASN
[patent_app_type] => utility
[patent_app_number] => 16/566119
[patent_app_country] => US
[patent_app_date] => 2019-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48342
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 150
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16566119
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/566119 | Compounds and compositions for inhibition of FASN | Sep 9, 2019 | Issued |
Array
(
[id] => 16460735
[patent_doc_number] => 10844069
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-11-24
[patent_title] => Pyrrolotriazine compounds as TAM inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/559841
[patent_app_country] => US
[patent_app_date] => 2019-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69247
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16559841
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/559841 | Pyrrolotriazine compounds as TAM inhibitors | Sep 3, 2019 | Issued |
Array
(
[id] => 16236703
[patent_doc_number] => 20200253937
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME
[patent_app_type] => utility
[patent_app_number] => 16/541337
[patent_app_country] => US
[patent_app_date] => 2019-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31726
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16541337
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/541337 | 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | Aug 14, 2019 | Abandoned |
Array
(
[id] => 16125837
[patent_doc_number] => 10696658
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-30
[patent_title] => Heteroaromatic compounds and their use as dopamine D1 ligands
[patent_app_type] => utility
[patent_app_number] => 16/539865
[patent_app_country] => US
[patent_app_date] => 2019-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45557
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1304
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16539865
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/539865 | Heteroaromatic compounds and their use as dopamine D1 ligands | Aug 12, 2019 | Issued |
Array
(
[id] => 15163165
[patent_doc_number] => 10487062
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2019-11-26
[patent_title] => Regioselective one-step process for synthesizing 2-hydroxyquinoxaline
[patent_app_type] => utility
[patent_app_number] => 16/529371
[patent_app_country] => US
[patent_app_date] => 2019-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2772
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 212
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16529371
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/529371 | Regioselective one-step process for synthesizing 2-hydroxyquinoxaline | Jul 31, 2019 | Issued |
Array
(
[id] => 15342505
[patent_doc_number] => 20200009144
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-09
[patent_title] => Combination Therapy Comprising Varlitinib and an Anticancer Agent
[patent_app_type] => utility
[patent_app_number] => 16/508444
[patent_app_country] => US
[patent_app_date] => 2019-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7766
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16508444
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/508444 | Combination therapy comprising Varlitinib and an anticancer agent | Jul 10, 2019 | Issued |
Array
(
[id] => 16444842
[patent_doc_number] => 10836754
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-11-17
[patent_title] => Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
[patent_app_type] => utility
[patent_app_number] => 16/503245
[patent_app_country] => US
[patent_app_date] => 2019-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 5180
[patent_no_of_claims] => 33
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16503245
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/503245 | Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol | Jul 2, 2019 | Issued |
Array
(
[id] => 15264639
[patent_doc_number] => 20190381053
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-19
[patent_title] => METHODS OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/458546
[patent_app_country] => US
[patent_app_date] => 2019-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20308
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16458546
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/458546 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | Jun 30, 2019 | Issued |